- Current report filing (8-K)
January 27 2010 - 5:14PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Filed Pursuant to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report
(Date
of earliest event reported): January 27, 2010
Repros
Therapeutics Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-15281
|
76-0233274
|
(State
or other jurisdiction of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
2408
Timberloch Place, Suite B-7
The
Woodlands, Texas 77380
(Address
of principal
executive
offices
and
zip code)
|
|
(281)
719-3400
(Registrant’s
telephone number, including area code)
|
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events.
On
January 27, 2010, Repros Therapeutics Inc. (the “Company”) issued a press
release titled “Repros Receives Guidance from FDA Regarding Continued
Development of Androxal
®
in Hypogonadal Men.” The press release contains a summary of certain
guidance received from the Food and Drug Administration regarding the Company’s
development of its oral Androxal
®
product. A copy of such press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
.
|
Exhibit
|
|
|
Number
|
Description
|
|
|
|
|
99.1
|
Press
Release dated January 27,
2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Repros
Therapeutics Inc.
|
|
|
|
|
|
Date: January
27, 2010
|
By:
|
/s/
Joseph S. Podolski
|
|
|
|
Joseph
S. Podolski
|
|
|
|
President
and Chief Executive Officer
|
|
EXHIBIT
INDEX
|
Exhibit
|
|
|
Number
|
Description
|
|
|
|
|
99.1
|
Press
Release dated January 27, 2010
|
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024